Axol Bioscience

20 articles with Axol Bioscience

• 

  BioSpace Global Roundup: Antiverse Scores $2 Million to Advance AI Antibody P...

  3/18/2021

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Axol Bioscience and Censo Biotechnologies Announce Merger

  3/17/2021

  Merger accompanied by £3.8million ($5.3m USD) investment across shareholders, which will be used to fund recruitment and growth of the business

• 

  BioSpace Movers & Shakers, Jan. 15

  1/15/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers.

• Axol Bioscience Strengthens Commercial Leadership Team With Key Appointments

  1/13/2021

  Axol Bioscience, a biotechnology company specializing in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, announced the appointment of Ross Wheatcroft as the Global Strategic Accounts Manager.

• 

  BioSpace Global Roundup, Oct. 15

  10/15/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Axol Bioscience Introduces Multi-Electrode Array Screening Services for Human iPSC-Derived Cells

  10/13/2020

  New services combine the Company’s iPSC-derived human cells and electrophysiological expertise with Axion Biosystems’ Maestro Pro MEA platform

• 

  BioSpace Movers & Shakers, Aug. 28

  8/28/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Axol Bioscience appoints Liam Taylor as Chief Executive Officer

  8/27/2020

  Axol Bioscience, a biotechnology company specializing in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, today announced the appointment of Liam Taylor as CEO. Liam will guide the growth of the Company, and will focus on maximizing the potentia

• Axol Bioscience Launches Human iPSC-derived Microglia

  12/6/2018

  Axol Bioscience, the human cell culture specialist, is launching a new line of Human induced Pluripotent Stem Cells (iPSC)-derived Microglia for the consistent and reproducible study of neuroglia and their involvement in neurodegenerative diseases, including Alzheimer’s disease, multiple sclerosis and Parkinson’s disease. 

• Axol Bioscience Opens US Office

  9/20/2018

  Axol, the rapidly growing specialist in human cell culture, is delighted to announce it has opened a new operational hub in the US.

• Axol Bioscience Launch Human iPSC-derived Atrial Cardiomyocytes

  7/23/2018

  Axol Bioscience, launch their Human iPSC-derived Atrial Cardiomyocytes for the discovery and development of novel treatments and advancing our understanding of cardiovascular disease.

• Specialist Stem Cell Biotech Axol Enhances Its Future Scientific And Commercial Endeavours

  8/22/2017

• Axol And Metrion Biosciences Announce Research Collaboration

  7/26/2016

• Axol Release: MESO-BRAIN Initiative Receives €3.3 Million To Replicate Brain’s Neural Networks Through 3D Nanoprinting

  6/9/2016

• Axol To Launch Novel iPSC-Derived Cells At ISSCR 2016

  6/1/2016

• Axol Launches iPSC-Derived Astrocyte Kits

  5/12/2016

• Axol Announces Custom Cell And Tissue Sourcing Service

  4/28/2016

• Axol Appoints Steve Finkbeiner As Scientific Advisory Board Member

  4/19/2016

• Axol Bioscience Appoints Paul Andrews To Scientific Advisory Board

  2/23/2016

• Axol Announces Chas Bountra As Scientific Advisory Board Member

  1/28/2016